Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Chou, Sherry [VerfasserIn]   i
 Macdonald, R. Loch [VerfasserIn]   i
 Keller, Emanuela [VerfasserIn]   i
 Etminan, Nima [VerfasserIn]   i
 Hackenberg, Katharina [VerfasserIn]   i
Titel:Biospecimens and molecular and cellular biomarkers in aneurysmal subarachnoid hemorrhage studies
Titelzusatz:common data elements and standard reporting recommendations
Verf.angabe:Sherry H.-Y. Chou, R. Loch Macdonald and Emanuela Keller on behalf of the Unruptured Intracranial Aneurysms and SAH CDE Project Investigators
E-Jahr:2019
Jahr:29 May 2019
Umfang:14 S.
Fussnoten:Gesehen am 01.10.2019
Titel Quelle:Enthalten in: Neurocritical care
Ort Quelle:New York, NY : Springer, 2004
Jahr Quelle:2019
Band/Heft Quelle:30(2019), 1, Seite 46-59
ISSN Quelle:1556-0961
Abstract:Development of clinical biomarkers to guide therapy is an important unmet need in aneurysmal subarachnoid hemorrhage (SAH). A wide spectrum of plausible biomarkers has been reported for SAH, but none have been validated due to significant variabilities in study design, methodology, laboratory techniques, and outcome endpoints.MethodsA systematic review of SAH biomarkers was performed per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The panel’s recommendations focused on harmonization of (1) target cellular and molecular biomarkers for future investigation in SAH, (2) standardization of best-practice procedures in biospecimen and biomarker studies, and (3) experimental method reporting requirements to facilitate meta-analyses and future validation of putative biomarkers.ResultsNo cellular or molecular biomarker has been validated for inclusion as “core” recommendation. Fifty-four studies met inclusion criteria and generated 33 supplemental and emerging biomarker targets. Core recommendations include best-practice protocols for biospecimen collection and handling as well as standardized reporting guidelines to capture the heterogeneity and variabilities in experimental methodologies and biomarker analyses platforms.ConclusionSignificant variabilities in study design, methodology, laboratory techniques, and outcome endpoints exist in SAH biomarker studies and present significant barriers toward validation and translation of putative biomarkers to clinical use. Adaptation of common data elements, recommended biospecimen protocols, and reporting guidelines will reduce heterogeneity and facilitate future meta-analyses and development of validated clinical biomarkers in SAH.
DOI:doi:10.1007/s12028-019-00725-4
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: http://dx.doi.org/10.1007/s12028-019-00725-4
 Verlag: https://doi.org/10.1007/s12028-019-00725-4
 DOI: https://doi.org/10.1007/s12028-019-00725-4
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Apolipoprotein E
 B-type natriuretic peptide
 Biomarkers
 Biospecimens
 Cardiac troponin I
 Cerebrospinal fluid
 common data elements
 interleukin-6
 metalloproteinase-9
 Plasma-type gelsolin
 S100β
 Standard operating procedure
 Subarachnoid hemorrhage
 Tumor necrosis factor alpha
K10plus-PPN:1677968168
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68434543   QR-Code
zum Seitenanfang